Cyprotex
Brett Litten is a seasoned professional with extensive experience in automation and software engineering, currently serving as Team Leader in Information Systems, Automation & Software Engineering at Cyprotex since March 2018. Prior to this role, Brett held the position of Automation Lead at Premaitha Health PLC, specializing in CE-IVD certified product development for Non-Invasive Prenatal Testing. An academic background includes a Doctor of Philosophy in Microfluidics related to Drug Discovery Screening from The University of Manchester, alongside a BSc (Hons) in Chemical & Analytical Science from Swansea University. Previous roles at AstraZeneca involved senior research and design of automated high throughput screening campaigns across several therapeutic areas, as well as significant contributions to drug metabolism and pharmacokinetics. Early career experience includes work as a Radioisotope QC Analyst at Nycomed Amersham. Brett possesses expertise with various high-tech automation equipment and assay processes across pharmacology and drug discovery domains.
This person is not in any teams
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology